Global plagues and the Global Fund: Challenges in the fight against HIV, TB and malaria
Tóm tắt
Although a grossly disproportionate burden of disease from HIV/AIDS, TB and malaria remains in the Global South, these infectious diseases have finally risen to the top of the international agenda in recent years. Ideal strategies for combating these diseases must balance the advantages and disadvantages of 'vertical' disease control programs and 'horizontal' capacity-building approaches. The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) represents an important step forward in the struggle against these pathogens. While its goals are laudable, significant barriers persist. Most significant is the pitiful lack of funds committed by world governments, particularly those of the very G8 countries whose discussions gave rise to the Fund. A drastic scaling up of resources is the first clear requirement for the GFATM to live up to the international community's lofty intentions. A directly related issue is that of maintaining a strong commitment to the treatment of the three diseases along with traditional prevention approaches, with the ensuing debates over providing affordable access to medications in the face of the pharmaceutical industry's vigorous protection of patent rights. At this early point in the Fund's history, it remains to be seen how these issues will be resolved at the programming level. Nevertheless, it is clear that significant structural changes are required in such domains as global spending priorities, debt relief, trade policy, and corporate responsibility. HIV/AIDS, tuberculosis and malaria are global problems borne of gross socioeconomic inequality, and their solutions require correspondingly geopolitical solutions.
Tài liệu tham khảo
World Health Organization: World Health Report. 2002, [http://www.who.int/whr/2002/en/]
McNeil WH: Plagues and Peoples. Toronto, Doubleday. 1989
Price-Smith AT: Contagion and Chaos: Infectious Disease and its effects on Global Security and Development. University of Toronto Centre for International Studies Working Paper 1998–001. 1998
National Intelligence Council: The Global Infectious Disease Threat and Its Implications for the United States. NIE 99-17D. January 2000, [http://www.odci.gov/cia/publications/nie/report/nie99-17d.html]
Ross S: Clinton calls AIDS threat to world security. Associated Press Newswires. 12/01/2000
Menzies D: Tuberculosis crosses borders. Int J Tuberc Lung Dis. 2000, 4 (12): S153-59.
Kaul I, Faust M: Global public goods and health: taking the agenda forward. Bull World Health Organ. 2001, 79: 869-874.
World Health Organization, Global Tuberculosis Programme: Treatment of Tuberculosis: Guidelines for National Programmes. World Health Organization. 1997, 2
The World Bank: Investing in Health: World Development Report 1993. Oxford, Oxford University Press. 1993
Khatri GR, Frieden TR: Controlling Tuberculosis in India. N Engl J Med. 2002, 347: 1420-1425. 10.1056/NEJMsa020098.
China Tuberculosis Control Collaboration: Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. Lancet. 1996, 347: 358-362. 10.1016/S0140-6736(96)90537-1.
Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM: Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet. 2001, 358: 410-414. 10.1016/S0140-6736(01)05551-9.
Health Canada: Declaration of Commitment on HIV/AIDS. Report on the United Nations General Assembly Special Session (UNGASS) on HIV/AIDS. 2001
Garner P: What makes DOT work? Directly observed therapy. Lancet. 1998, 352: 1326-1327.
Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M: Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet. 1998, 352: 1340-1343. 10.1016/S0140-6736(98)04022-7.
Walley JD, Khan MA, Newell JN, Khan MH: Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet. 2001, 357: 664-669. 10.1016/S0140-6736(00)04129-5.
Moore P: DOTS: what's in a name. Lancet. 2001, 357: 940-
Shafer J, Falzon D, Small I, Kittle D, Ford N: DOTS in Aral Sea area. Lancet. 2001, 358: 2001-10.1016/S0140-6736(01)06995-1.
Blower SM, Small PM, Hopewell PC: Control strategies for tuberculosis epidemics: new models for old problems. Science. 1996, 273: 497-500.
Farmer P: Infections and Inequalities: the Modern Plagues. Berkeley, University of California Press. 1999
Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC: Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis: Treatment Outcomes in 6 Countries. JAMA. 2000, 283: 2537-2545. 10.1001/jama.283.19.2537.
Benatar SR: Prospects for global health: lessons from tuberculosis. Thorax. 1995, 50: 487-489.
Benatar SR: Respiratory health in a globalizing world. Am J Respir Crit Care Med. 2001, 163: 1064-1067.
Performance and Innovation Unit: Tackling the Diseases of Poverty: A Report by the PIU. [http://www.cabinet-office.gov.uk/innovation/2001/health/healthreport/01/content01.htm]
International Conference on Primary Health Care: Declaration of Alma-Ata. [http://www.who.int/hpr/archive/docs/almaata.html]
Harrold P, and associates: The broad sector approach to investment lending. World Bank Discussion Papers, Africa Technical Department Series, no 302, World Bank. 1995
Cassels A, Janovsky K: Better health in developing countries: are sector-wide approaches the way of the future?. Lancet. 1998, 352: 1777-1779. 10.1016/S0140-6736(98)05350-1.
Peters A, Chao S: The sector-wide approach in health: What is it? Where is it leading?. Int J Health Plann Mgmt. 1998, 13: 177-190. 10.1002/(SICI)1099-1751(199804/06)13:2<177::AID-HPM504>3.0.CO;2-T.
Bosman MC: Health sector reform and tuberculosis control: the case of Zambia. Int J Tuberc Lung Dis. 2000, 4: 606-614.
Johns Hopkins University Center for AIDS Research: Global Fund to Fight AIDS, Tuberculosis and Malaria (GFTM) Technical Consultation. October 30–31 2001, [http://www.globalfundatm.org/publicdoc/globalAIDSExecSummaryfinal1105.pdf]
Farmer P, Léandre F, Mukherjee JS, Claude MS, Nevil P, Smith-Fawzi MC, Koenig SP, Castro A, Becerra MC, Sachs J, Attaran A, Kim JY: Community-based approaches to HIV treatment in resource-poor settings. Lancet. 2001, 358: 404-409. 10.1016/S0140-6736(01)05550-7.
Farmer P, Kim JY: Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". BMJ. 1998, 317: 671-674.
Farmer PE, Furin JJ, Shin SS: The clinical management of multidrug-resistant tuberculosis. J Respir Dis. 2000, 21: 53-56.
Tahaogl K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, Özmen I, Kapakli N: The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001, 345: 170-174. 10.1056/NEJM200107193450303.
Gupta R, Kim JY, Espinal MA, Caudron J-M, Pecoul B, Farmer PE, Raviglione MC: Responding to Market Failures in Tuberculosis Control. Science. 2001, 293: 1049-1051. 10.1126/science.1061861.
The Global Fund to Fight AIDS, Tuberculosis and Malaria. [http://www.globalfundatm.org/files/Financial_contributions_011002.htm]
New York Times: "Combating AIDS in the Third World.". April 27, 2002, [http://www.nytimes.com/2002/04/27/opinion/_27SAT3.html]
Brugha R, Walt G: A global health fund: a leap of faith?. BMJ. 2001, 323: 152-154. 10.1136/bmj.323.7305.152.
EL Corbett, RW Steketee, ter Kuile FO, AS Latif, A Kamali, RJ Hayes: HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet. 2002, 359: 2177-2187. 10.1016/S0140-6736(02)09095-5.
Feachem R: Senior Lecture, 9 July XIV International AIDS Conference, Barcelona. 2002, [http://www.globalfundatm.org/journalists/speeches/speech_Feachem090702.html]
World Health Organization. [http://www.who.int/medicines/]
P Trouiller, P Olliaro, E Torreele, J Orbinski, R Laing, N Ford: Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002, 359: 2188-2194. 10.1016/S0140-6736(02)09096-7.
Ford N, 't Hoen T: The Global Health Fund: moral imperative or industry subsidy?. Lancet. 2001, 58: 578-10.1016/S0140-6736(01)05711-7.
Pecoul B: MSF Open Letter to TWG and TSS. [http://archives.hst.org.za/bts/msg00053.html]
Ellman T, Ford N, Brugha R: First round of payments from the Global Fund. Lancet. 2002, 360: 262-10.1016/S0140-6736(02)09485-0.
World Trade Organization: Doha Ministerial Declaration on the TRIPS Agreement and Public Health, para 4. WTO Doc No WT/MIN(01)/DEC/2. 2001
Attaran A, Sachs J: Defining and refining international donor support for combating the AIDS pandemic. Lancet. 2001, 357: 57-61. 10.1016/S0140-6736(00)03576-5.
Teklehaimanot A, Snow CP: Will the Global Fund help roll back malaria in Africa?. Lancet. 2002, 360: 888-889. 10.1016/S0140-6736(02)11069-5.
US Department of Homeland Security. [http://www.whitehouse.gov/news/releases/2002/02/20020204-2.html]
Lewis S: Keynote Address, G6B People's Summit, Calgary, Canada. 21 June 2002
Report of the Commission on Macroeconomics and Health Macroeconomics and Health: Investing in Health for Economic Development, 20 December. 20 December 2001, [http://www3.who.int/whosis/cmh/cmh_report/e/report.cfm?path=cmh,cmh_report&language=english]
Sachs J: The Strategic Significance of Global Inequality. The Washington Quarterly. 2001, 24: 187-198. 10.1162/01636600152102331.
Editorial: Grants, not loans, for the developing world?. Lancet. 2001, 357: 1-10.1016/S0140-6736(00)03557-1.
Froning D: Will Debt Relief Really Help?. The Washington Quarterly. 2001, 24: 199-211. 10.1162/01636600152102340.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-698X/3/2/prepub